The IGF2BP1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line. This product enables loss-of-function studies of IGF2BP1, an mRNA-binding protein central to post-transcriptional gene regulation and oncogenic signaling. The polyclonal format offers a heterogeneous collection of knockout cells, minimizing clonal artifacts and providing a robust system for genomic and phenotypic investigations.
The A-549 cell line is a well-established model of lung adenocarcinoma, originally isolated from a human lung carcinoma and widely utilized in cancer and drug metabolism research. It harbors key genetic alterations such as KRAS and STK11 mutations, which drive malignant behavior and make it highly relevant for studying non-small cell lung carcinoma (NSCLC). This background provides a clinically meaningful platform for examining the role of RNA-binding proteins in tumor progression.
IGF2BP1 regulates the stability, translation, and subcellular localization of target mRNAs, functioning downstream of the beta-catenin/TCF complex and the MYC transcription factor. It forms complexes with RNA-binding proteins including HUR, LIN28B, IMP2, and IMP3 to control the expression of oncogenic transcripts such as MYC, ACTB, CD44, and GLI1. Through these interactions, IGF2BP1 promotes cell proliferation, cytoskeletal dynamics, and invasive behavior, while also influencing mTOR signaling. Knockout of IGF2BP1 disrupts these regulatory networks, leading to impaired translation of key mRNAs and attenuation of Wnt/??-catenin-mediated transcriptional programs.
In A-549 cells, loss of IGF2BP1 dampens Wnt and MYC activity, reducing cell migration and invasion and potentially sensitizing cells to chemotherapeutic agents. This model is particularly suited to dissect the intersection of post-transcriptional control and oncogenic signaling in NSCLC, allowing researchers to interrogate how IGF2BP1 affects tumor maintenance, epithelial-to-mesenchymal transition, and drug sensitivity. It provides a valuable tool for identifying vulnerabilities in lung adenocarcinoma and other IGF2BP1-overexpressing cancers.
These cells support a wide range of applications, including analysis of mRNA stability and translation via actinomycin D chase and polysome profiling, investigation of RNA-protein interactions by RNA immunoprecipitation, and protein/gene expression studies by western blotting and RT-qPCR. Functional assays such as wound healing, transwell invasion, and cell proliferation enable assessment of phenotypic consequences of IGF2BP1 loss. The model is also useful for drug resistance studies, evaluating how post-transcriptional regulation modifies therapeutic response. For further information or batch-specific validation, please contact Ascent Research.
